NCT07181837 (ASCEND-AS) is a Phase 1, PHASE2 clinical trial of MVX-220 in Angelman Syndrome, sponsored by MavriX Bio, LLC.

Who is sponsoring NCT07181837?

NCT07181837 is sponsored by MavriX Bio, LLC.

What drugs are being tested in NCT07181837?

Interventions in NCT07181837: MVX-220.

What condition does NCT07181837 study?

NCT07181837 studies Angelman Syndrome.

Is NCT07181837 still recruiting?

NCT07181837 is currently recruiting now. Last updated 16 March 2026.

Last reviewed 2026-03-16 · How we verify

NCT07181837: ASCEND-AS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 1/2 Study of the Safety and Efficacy of MVX-220 in Angelman Syndrome

Recruiting now Phase 1, PHASE2 Last updated 16 March 2026

What this trial tests

Phase 1, PHASE2 trial testing MVX-220 in Angelman Syndrome in 12 participants. Currently enrolling.

Timeline

29 October 2025

Primary endpoint
31 March 2028

31 May 2031

Quick facts

Lead sponsor	MavriX Bio, LLC
Phase	Phase 1, PHASE2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	12
Start date	29 October 2025
Primary completion	31 March 2028
Estimated completion	31 May 2031
Sites	3 locations across United States

Drugs / interventions tested

MVX-220

Conditions studied

Angelman Syndrome — all drugs for Angelman Syndrome →

Sponsor

MavriX Bio, LLC — full company profile →

Who can join

Adults 4 to 50, any sex, with Angelman Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the safety and efficacy of MVX-220 gene therapy in children and adults with Angelman syndrome with UBE3A gene deletion, uniparental disomy, or imprinting center defect genotypes.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Crossing the finish line towards a disease-modifying treatment for Angelman syndrome.
Judson MC, de Almeida LP, Burdine RD, Chamberlain SJ, et al · · 2026 · PMID 41795090 · DOI 10.1186/s11689-026-09681-5

Verify or expand the search:

Other recruiting trials for Angelman Syndrome

Currently open trials in the same condition.

NCT06353620 — Structural-functional Connectome in Drug-resistant Epilepsies and Neurodevelopmental Syndromes With Epilepsy · recruiting
NCT06115109 — Angelman Natural History Study - FAST Spain · recruiting
NCT05293184 — The Global Angelman Syndrome Registry · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07181837 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by MavriX Bio, LLC
Last refreshed: 16 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07181837.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing